Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 14/20 | 0.60 |
| ▸ | DRD2 | P14416 | 12/20 | 0.60 |
| ▸ | HTR1A | P08908 | 2/20 | 0.49 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL10847216 | 0.89 | DRD3 (0.58) | DRD3DRD2HTR1AFYN | |
| Bromide SCHEMBL10759133 | 0.87 | DRD2 (0.55) | DRD3DRD2HTR1AFYN | |
| SCHEMBL10754236 | 0.83 | DRD2 (0.59) | DRD3DRD2HTR1AFYNDRD4 | |
| SCHEMBL10761230 | 0.83 | DRD2 (0.66) | DRD3DRD2HTR1AFYN | |
| SCHEMBL10761186 | 0.82 | DRD2 (0.60) | DRD3DRD2HTR1AFYN | |
| Hydrochloric Acid SCHEMBL10763527 | 0.82 | DRD2 (0.64) | DRD3DRD2HTR1AFYN | |
| Hydrochloric Acid SCHEMBL10761212 | 0.82 | DRD2 (0.57) | DRD3DRD2HTR1AFYNDRD4 | |
| SCHEMBL10762873 | 0.81 | DRD2 (0.56) | DRD3DRD2HTR1AFYNDRD4 | |
| SCHEMBL10755730 | 0.81 | DRD2 (0.62) | DRD3DRD2HTR1AFYN | |
| Hydrochloric Acid SCHEMBL10850176 | 0.80 | DRD2 (0.61) | DRD3DRD2HTR1AFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0209983-A1 | Dialkylaminotetrahydroquinazoline | ELI LILLY AND COMPANY (US) | 1987-01-28 | — | — | EP | claimed |
| US-4622398-A | INCREASING CONCENTRATION OF DOPAMINE AND NOREPINEPHRINE IN BRAIN, ANTAGONIST | ELI LILLY AND COMPANY (US) | 1986-11-11 | — | — | US | claimed |
| US-20070117788-A1 | Combination of a dopamine D2-receptor agonist and tiotropium or a derivative therof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-05-24 | — | — | US | disclosed |
| US-20070117788-A1 | Combination of a dopamine D2-receptor agonist and tiotropium or a derivative therof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-05-24 | — | — | US | disclosed |
| EP-0209983-A1 | Dialkylaminotetrahydroquinazoline | ELI LILLY AND COMPANY (US) | 1987-01-28 | — | — | EP | disclosed |
| US-4622398-A | INCREASING CONCENTRATION OF DOPAMINE AND NOREPINEPHRINE IN BRAIN, ANTAGONIST | ELI LILLY AND COMPANY (US) | 1986-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117788-A1 | Combination of a dopamine D2-receptor agonist and tiotropium or a derivative therof for treating obstructive airways and other inflammatory diseases | CHRM2, ADRB2, CHRM3 | DRD3 39/4885DRD2 33/4885HTR1A 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.